<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01907529</url>
  </required_header>
  <id_info>
    <org_study_id>HBMUFH-101</org_study_id>
    <nct_id>NCT01907529</nct_id>
  </id_info>
  <brief_title>A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer</brief_title>
  <acronym>TENDENCY</acronym>
  <official_title>A Trail of Neoadjuvant Endostar in Combination With Docetaxel, Epirubicin and Cyclophosphamide in Patients With Stage III Breast Cancer (TENDENCY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin
      in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for
      breast cancer patients. The hypothesis of this protocol is that the combined an active
      angiogenesis agent to chemotherapy could enhance the pathological responce rate and further
      benefit breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical/pathological response</measure>
    <time_frame>48 months</time_frame>
    <description>The clincial response will be evaluated according to RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Stage III Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemo plus Endostar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel, epirubicin and cyclophosphamide plus endostar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemo only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel, epirubicin and cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, epirubicin and cyclophosphamide</intervention_name>
    <description>docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles</description>
    <arm_group_label>Chemo only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, epirubicin and cyclophosphamide plus endostar</intervention_name>
    <description>docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles</description>
    <arm_group_label>Chemo plus Endostar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer
             diagnosis and fine needle aspiration for lymph node metastasis diagnosis)

          -  Age 18-70

          -  No evidence of distant metastasis

          -  No previous therapy

          -  Normal hematologic function

          -  No abnormality of renal or liver function

          -  Written informed consent

        Exclusion Criteria:

          -  With allergic constitution or possible allergic reflection to drugs to be used in this
             study

          -  Any concurrent uncontrolled medical or psychiatric disorder

          -  History of severe heart diseases, including congestive heart failure, unstable angina,
             uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or
             heart valve disease

          -  Being pregnant or nursing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YUNJIANG LIU, M.D.&amp; PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Fourth Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunjiang Liu, M.D.&amp; PhD.</last_name>
    <phone>+86-13703297890</phone>
    <email>lyj818326@126.com</email>
  </overall_contact>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Yunjiang Liu</investigator_full_name>
    <investigator_title>M.D, Chief Physician of Breast Cancer Dept, Vice-President of Hebei Medical University Fourth Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

